Menu
If you are a senior biopharma executive, you know it’s hard to find a safe forum of peers to ideate on the biggest issues facing the industry.
In July 2018, our Founder, Frank F. Dolan, brought 40 ambitious executives into a room for 2 days to shape and share best practices. Not a conference, no exhibit halls, no vendors- just peers from different companies with a shared vision: to improve and extend patients’ lives.
The feedback was clear: connecting great people and ideas can transform the industry.
Today, ARSENAL connects the people and ideas transforming the life science industry. Powered by experience and peer-to-peer exchange, we shape and share best practices to unlock brand potential.
We serve three constituencies. For:
If you’ve been in biopharma for more than 5 minutes, you know this is an industry with a fair amount of politics and processes that slow down innovation. If you are a patient in need of therapy that isn’t available yet, every day counts.
When we enable senior executives to explore people and ideas outside their company they find ways to perform at higher levels and innovate at a faster pace.
History dictates that societies that don’t collaborate are destined to fall. We are playing a role in helping the industry come together to accomplish our shared value: deliver for the patient.
At some point, we are all patients.
Frank is a founding commercial member of Takeda, Amylin, and Acadia Pharmaceuticals. His deep industry experience includes launching commercial functions and over a dozen products leading to over $100 billion in mergers and acquisitions.
ARSENAL ADVISORS drives innovation across industries by connecting people, ideas, and cutting-edge technology, reshaping the future of business with strategic insights and actionable intelligence.